一个小的设备可以为患有囊性纤维化恶化的患者提供大尺寸的解决方案
P Laird1,2, G MacKenzie1, F Gill3
1Physiotherapy Department, Perth Children's Hospital, Perth, Western Australia, Australia.
International journal of pediatrics
|December 2, 2024
概括
囊性纤维化抗生素治疗的便携式弹输注器设备改善了患者的活动,减少了住院时间,与标准输注相比,大大节省了成本.
科学领域:
- 儿科肺病学 儿科肺病学
- 医疗器械技术 医疗器械技术
- 卫生经济学 卫生经济学
背景情况:
- 身体活动对患有囊性纤维化 (CF) 的儿童至关重要,以提高福祉和健康结果.
- 便携式弹输注器为患者提供了输入静脉抗生素的首选方法.
- 目前对CF恶化的治疗方案通常涉及标准输液 (SIP).
研究的目的:
- 为了比较弹输注器设备与SIP在治疗CF恶化中的疗效.
- 评估对患者健康结果的影响,住院时间 (LoS) 和治疗费用.
- 在住院期间评估儿科CF患者的体力活动水平.
主要方法:
- 一项观察性队列研究,涉及患有CF恶化症的儿科患者 (8-19岁).
- 活动监测器记录了入院后的最后5天的身体活动.
- 与弹输注器与SIP抗生素输送相关的LoS和成本的比较.
主要成果:
- 使用弹输注器的参与者与使用SIP的参与者相比,表现出更高的体力活动 (更高的步数).
- 在弹输注器组 (12.4天) 和SIP组 (16.1天) 中,平均LOS降低.
- 春季输注器的使用导致每名儿童估计节省了大约12,000澳元的成本.
结论:
- 弹输注器设备可能会促进患有CF的住院儿童增加体力活动.
- 随着弹输注器的使用,观察到减少的LoS和相关的成本节约.
- 住院CF患者目前的体力活动水平低于推水平.
更多相关视频
06:57The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
9.2K
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.2K
相关概念视频
Cystic Fibrosis: Management
141
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
141
Cystic Fibrosis: Pathogenesis
186
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
186
Inhaled Medications
237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
COPD: Management Using Bronchodilators and Corticosteroids
178
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
178
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349
